Cetuximab is first to extend survival for those resistant to chemotherapy, study says
WEDNESDAY, Nov. 14 (HealthDay News) -- A highly targeted biologic drug called cetuximab (Erbitux) is the first to extend the survival of patients with advanced colon cancer who have otherwise proved resistant to conventional chemotherapy, Canadian researchers confirmed.
But the drug, which costs $12,000 a month in the United States, appears to be effective in only about one-third of colon tumors, based on their specific gene profile, experts added.
"That's a significant number, but it still leaves a large proportion [of patients] who aren't benefiting," noted lead researcher Dr. Derek Jonker, assistant professor of medicine at the University of Ottawa and a medical oncologist at the Ottawa Hospital.
Nevertheless, the success of any new drug is welcome, he added.
"Until now, no anticancer therapy had demonstrated an improvement in survival in patients for whom chemotherapy was no longer effective, and for whom supportive care was the only available treatment," Jonker said. "So, cetuximab provides new hope for these patients."
The findings were reported in the Nov. 15 issue of the New England Journal of Medicine. The study was funded by the National Cancer Institute of Canada, as well as ImClone Systems and Bristol-Myers Squibb, the two companies that developed the drug.
Colorectal cancer is the third most common kind of cancer and the third leading cause of cancer death in the United States. As Jonker explained, most patients are treated with either surgery or conventional chemotherapy, which typically targets cellular DNA.
Unfortunately, almost all patients with advanced or metastasized colon cancer will develop resistance to standard chemotherapy drugs, he said.
"However, now we have a new class of drugs known as the biologically targeted therapies, such as cetuximab, and these drugs are targeted to different aspects of the tumor biology," Jonker explained. "Many of them are targeted at receptors or signals that trigger a cancer cell to grow."
In the case of cetuximab, the drug's target is the epidermal growth factor receptor (EGFR), which is found in especially high concentrations on colon cancer cells. Because biologic drugs are finely targeted to affect cancer cells and not healthy cells, they typically have fewer side effects than standard chemotherapy.
In 2004, the U.S. Food and Drug Administration granted cetuximab conditional approval for use in patients with late-stage, chemotherapy-resistant colon cancer. At the time, the agency stated that full approval hinged on the outcome of the Canadian trial.
In October, and based on the new findings, the agency followed through and gave the drug its full approval for this new indication.
In the trial, Jonker's team administered individualized doses of cetuximab to 287 colon cancer patients treated between late 2003 and August 2005. All of the patients had proven resistant to standard chemotherapy. Another 285 patients received supportive/palliative care only -- the usual option for patients in this situation.
Compared to those who didn't receive the drug, overall survival for patients receiving cetuximab improved by 23 percent, while survival without any sign of disease progression rose by 32 percent, the research team reported.
The incidence of side effects -- including skin rash -- was 78.5 percent in the cetuximab group versus about 59 percent for the control group.
One key point, however, was that increases in survival were found only among the 31.4 percent of patients who actually responded to cetuximab, meaning that their cancer stopped growing.
That's probably due to the fact that cetuximab (as well as a related drug, panitumumab) only works against a specific subtype of colon cancer cell -- those carrying an unmutated version of a particular gene called KRAS.
"Mutated KRAS almost guarantees no benefit" from cetuximab, said one expert, Dr. Axel Grothey, a professor of oncology and chairman of the colorectal cancer group at the Mayo Clinic, in Rochester, Minn.
For that reason, he said, pre-treatment gene testing may prove crucial to decisions as to whether a particular patient receives cetuximab or not.
Because it is so expensive -- the costliest drug used today against colon cancer -- and because it can induce side effects, "I would like cetuximab to be used in a more individualized way," Grothey said.
He said that most cancer centers, including the Mayo Clinic, do not yet have technologies in place to test tumors for KRAS, but many are looking into it.
Jonker agreed that, ideally, KRAS testing and the use of cetuximab would go hand-in-hand. That way, he said, "We wouldn't have to put [patients] through treatment, and we wouldn't have to suffer the cost of treatment for people who may not even respond to the drug."
Studies are already under way to see if adding cetuximab to other therapies will boost survival even further, Jonker said. "The future of cetuximab is likely to be in combination with chemotherapy or other biologically targeted therapies, where the benefits of cetuximab might be further enhanced," he said.
The drug might also work better if given earlier in the disease process, before patients have developed resistance to chemotherapy.
In any case, the Canadian trial does give colon cancer patients some new reason for hope, Grothey said. "We need this drug," he said, "and we probably need it even earlier."
There's more on colon cancer at the American Cancer Society.
SOURCE: Derek Jonker, M.D., assistant professor, oncology, University of Ottawa, and medical oncologist, Ottawa Hospital, Ottawa, Ontario, Canada; Axel Grothey, professor, oncology, and chair, colorectal cancer group, Mayo Clinic, Rochester, Minn.; Nov. 15, 2007, New England Journal of Medicine
All rights reserved